1,541
Participants
Start Date
August 6, 2021
Primary Completion Date
October 27, 2021
Study Completion Date
November 22, 2022
Ad26.COV2.S
Participants will receive IM injection of Ad26.COV2.S.
Rochester Clinical Research, Inc, Rochester
Coastal Carolina Research Center, North Charleston
Accellacare US Inc, Mt. Pleasant
Velocity Clinical Research, Anderson, Anderson
Synexus Clinical Research US Inc, The Villages
Synexus Clinical Research US Inc, Orlando
Velocity Clinical Research, Hallandale Beach, Hallandale
Research Centers of America, LLC, Hollywood
University of Kentucky, Lexington
Optimal Research, Peoria
Johnson County Clin-Trials, Lenexa
Clinical Trials Management, LLC, Metairie
Crofoot Research Center, Houston
Velocity Clinical Research, Salt Lake City, West Jordan
Central Phoenix Medical Clinic, Phoenix
Synexus Clinical Research US Inc, Tucson
Ark Clinical Research, Long Beach
Velocity Clinical Research, North Hollywood
Anaheim Clinical Trials, LLC, Anaheim
Massachusetts General Hospital, Boston
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston
Janssen Vaccines & Prevention B.V.
INDUSTRY